23 reports of this reaction
3.5% of all BROMPHENIRAMINE MALEATE, DEXTROMETHORPHAN HYDROBROMIDE reports
#3 most reported adverse reaction
CONVULSION is the #3 most commonly reported adverse reaction for BROMPHENIRAMINE MALEATE, DEXTROMETHORPHAN HYDROBROMIDE, manufactured by Foundation Consumer Brands. There are 23 FDA adverse event reports linking BROMPHENIRAMINE MALEATE, DEXTROMETHORPHAN HYDROBROMIDE to CONVULSION. This represents approximately 3.5% of all 662 adverse event reports for this drug.
Patients taking BROMPHENIRAMINE MALEATE, DEXTROMETHORPHAN HYDROBROMIDE who experience convulsion should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CONVULSION is moderately reported among BROMPHENIRAMINE MALEATE, DEXTROMETHORPHAN HYDROBROMIDE users, representing a notable but not dominant share of adverse events.
In addition to convulsion, the following adverse reactions have been reported for BROMPHENIRAMINE MALEATE, DEXTROMETHORPHAN HYDROBROMIDE:
The following drugs have also been linked to convulsion in FDA adverse event reports:
CONVULSION has been reported as an adverse event in 23 FDA reports for BROMPHENIRAMINE MALEATE, DEXTROMETHORPHAN HYDROBROMIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
CONVULSION accounts for approximately 3.5% of all adverse event reports for BROMPHENIRAMINE MALEATE, DEXTROMETHORPHAN HYDROBROMIDE, making it one of the most commonly reported side effect.
If you experience convulsion while taking BROMPHENIRAMINE MALEATE, DEXTROMETHORPHAN HYDROBROMIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.